



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/658,699	09/09/2003	Christopher M. Starr	30610/30013A	2307
4743	7590	02/15/2005	EXAMINER	
MARSHALL, GERSTEIN & BORUN LLP 6300 SEARS TOWER 233 S. WACKER DRIVE CHICAGO, IL 60606			PAK, YONG D	
			ART UNIT	PAPER NUMBER
			1652	

DATE MAILED: 02/15/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	10/658,699	STARR, CHRISTOPHER M.	
	<b>Examiner</b>	<b>Art Unit</b>	
	Yong D Pak	1652	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) ☒ Responsive to communication(s) filed on 09 February 2004.
- 2a) ☐ This action is **FINAL**.                      2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) ☒ Claim(s) 33-41 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 33-41 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 9/9/03 is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \*    c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

- |  |   |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)  | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)   | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)             |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)<br>Paper No(s)/Mail Date <u>7/15/04</u> . | 6) <input type="checkbox"/> Other: _____  |

Art Unit: 1652

### **DETAILED ACTION**

This application is a divisional of 09/562,427, now abandoned.

The amendment filed on February 9, 2004, canceling claims 1-32 and adding claims 33-41, has been entered.

Claims 33-41 are pending. Claims 33-41 are under consideration.

### ***Information Disclosure Statement***

The information disclosure statement (IDS) submitted on July 15, 2004 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner.

### ***Drawings***

Drawings submitted in this application are accepted by the Examiner for examination purposes only.

### ***Claim Rejections - 35 USC § 112***

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Art Unit: 1652

Claims 33-41 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Claims 33-37 are drawn to a pharmaceutical composition comprising a N-acetylgalactosamine-4-sulfatase (ASB). Claims 38-41 are drawn to a pharmaceutical composition comprising human ASB. The claims encompass recombinants, variants and mutants of human ASB and any ASB. Therefore, the claims are drawn to a genus of polypeptides having any structure. The specification only teaches one species, a human ASB of 533 amino acids with a signal peptide of 41 amino acids (specification, page 11 and Peters et al. – form PTO-1449). One species is not enough to describe the whole genus and there is no evidence on the record of the relationship between the structure of this species and the structure of any recombinants, variants and mutants of any ASB. The specification also does not describe which residues of ASB are needed to impart a variant or mutant with ASB activity. Therefore, the specification fails to describe a representative species of the genus comprising variants and mutants of any ASB.

Given this lack of description of the representative species encompassed by the genus of the claims, the specification fails to sufficiently describe the claimed invention in such full, clear, concise, and exact terms that a skilled artisan would recognize that applicants were in possession of the inventions of claims 33-41.

Claims 33-41 are rejected under 35 U.S.C.. 112, first paragraph, because the specification, while being enabling for a pharmaceutical composition comprising human ASB taught by Peters et al., does not reasonably provide enablement for pharmaceutical compositions comprising any ASB. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make the invention commensurate in scope with these claims.

Factors to be considered in determining whether undue experimentation is required, are summarized in *In re Wands* (858 F.2d 731, 8 USPQ 2nd 1400 (Fed. Cir. 1988)) as follows: (1) the quantity of experimentation necessary, (2) the amount of direction or guidance presented, (3) the presence or absence of working examples, (4) the nature of the invention, (5) the state of the prior art, (6) the relative skill of those in the art, (7) the predictability or unpredictability of the art, and (8) the breadth of the claim(s).

Claims 33-37 are drawn to a pharmaceutical composition comprising a N-acetylgalactosamine-4-sulfatase (ASB). Claims 38-41 are drawn to a pharmaceutical composition comprising human ASB. The claims encompass recombinants, variants and mutants of human ASB and any ASB. Therefore, the scope of the claims is not commensurate with the enablement provided by the disclosure with regard to the extremely large number of ASB broadly encompassed by the claims. Since the amino acid sequence of a protein determines its structural and functional properties, predictability of which changes can be tolerated in a protein's amino acid sequence and

Art Unit: 1652

obtain the desired activity requires a knowledge of and guidance with regard to which amino acids in the protein's sequence, if any, are tolerant of modification and which are conserved (i.e. expectedly intolerant to modification), and detailed knowledge of the ways in which the proteins' structure relates to its function. However, in this case the disclosure is limited to the amino acid sequence of only one ASB. It would require undue experimentation of the skilled artisan to make and use the claimed polypeptides. The specification provides no guidance with regard to the making of variants and mutants or with regard to other uses. In view of the great breadth of the claim, amount of experimentation required to make the claimed polypeptides, the lack of guidance, working examples, and unpredictability of the art in predicting function from a polypeptide primary structure, the claimed invention would require undue experimentation. As such, the specification fails to teach one of ordinary skill how to use the full scope of the polypeptides encompassed by the claims.

While enzyme isolation techniques, recombinant and mutagenesis techniques are known, and it is routine in the art to screen for multiple substitutions or multiple modifications as encompassed by the instant claims, the specific amino acid positions within a protein's sequence where amino acid modifications can be made with a reasonable expectation of success in obtaining the desired activity/utility are limited in any protein and the result of such modifications is unpredictable. In addition, one skilled in the art would expect any tolerance to modification for a given protein to diminish with each further and additional modification, e.g. multiple substitutions.

The specification does not support the broad scope of the claims which encompass all modifications and fragments of any ASB because the specification does not establish: (A) regions of the protein structure which may be modified without affecting ASB activity; (B) the general tolerance of ASB to modification and extent of such tolerance; (C) a rational and predictable scheme for modifying any amino acid residue with an expectation of obtaining the desired biological function; and (D) the specification provides insufficient guidance as to which of the essentially infinite possible choices is likely to be successful.

Thus, applicants have not provided sufficient guidance to enable one of ordinary skill in the art to make and use the claimed invention in a manner reasonably correlated with the scope of the claims broadly including recombinants, variants and mutants of human ASB and any ASB. The scope of the claims must bear a reasonable correlation with the scope of enablement (*In re Fisher*, 166 USPQ 19 24 (CCPA 1970)). Without sufficient guidance, determination of ASB having the desired biological characteristics is unpredictable and the experimentation left to those skilled in the art is unnecessarily, and improperly, extensive and undue. See *In re Wands* 858 F.2d 731, 8 USPQ2nd 1400 (Fed. Cir, 1988).

Art Unit: 1652

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 33-41 are rejected under 35 U.S.C. 103(a) as being unpatentable over Crawly et al. and Mundorf et al. and Bam et al.

Claims 33-39 are drawn to a pharmaceutical composition comprising a recombinant N-acetylgalactosamine-4-sulfatase (ASB), polyoxyethylenesorbitan 20 or 80, and a carrier. Claims 40-41 are drawn to a pharmaceutical composition comprising a human N-acetylgalactosamine-4-sulfatase (ASB), polyoxyethylenesorbitan 20 or 80,



Art Unit: 1652

and a carrier, wherein the composition has the properties recited in claim 40 and are produced by the purification steps recited in claim 41.

Crawley et al. (form PTO-1449 – Reference C6) teaches a pharmaceutical composition comprising a human N-acetylgalactosamine-4-sulfatase (ASB) and a carrier (page 1865). The composition of Crawley et al. possesses the properties recited in claim 40 since the composition of Crawley and the instant invention contains the ASB of Peters et al. (page 1865). The protein of Crawley et al. was produced by the same purification process as recited in claim 41 (page 1865). However, Examiner notes that patentability of a product does not depend on the method used in producing the product (MPEP 2113).

The difference between the composition of Crawley and the instant invention is that the composition of Crawley et al. does not contain polyethylenesorbitan 20 or polyethylenesorbitan 20 (also known as polysorbate or tween).

Mundorf et al. (form PTO-892 – U.S. Patent No. 5,266,310) teaches that polysorbate 20 are stabilizing agents used in pharmaceutical compositions (Column 3). Mundorf et al. also teaches that the concentration of the polysorbates can be varied depending on the carrier used (Column 3). Bam et al. (form PTO-892) teaches that polysorbate 80 are stabilizing agents used in pharmaceutical compositions (page 258).

Combining the teachings of Crawley et al., Mundorf et al. and Bam et al., it would have been obvious to one having ordinary skill in the art use polysorbate 20 or polysorbate 80 in making the composition of Crawley et al. in order to prolong its shelf life. One of ordinary skill in the art would have been motivated to use polysorbate 20

Art Unit: 1652

or polysorbate 80 since Mundorf et al. and Bam et al. teach that polysorbates stabilize proteins in pharmaceutical compositions and prolong its shelf life. One of ordinary skill in the art would have had a reasonable expectation of success since Mundorf et al. and Bam et al. teach the use of polysorbate 20 or polysorbate 80 as stabilizing agents in pharmaceutical compositions and Crawley et al. successfully teaches pharmaceutical compositions comprising ASB and a carrier.

Therefore, the above references render claims 33-41 *prima facie* obvious to one of ordinary skill in the art.

### ***Double Patenting***

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 31-44 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-16 of copending Application No. 10/290,908. Although the conflicting claims are not identical, they are not patentably distinct from each other because they are claiming common

Art Unit: 1652

subject matter, as follows: Claims 33-36 and 38-39 of the instant application and claims 1-16 of 10/290,908 are both directed to a pharmaceutical compositions comprising ASB and polysorbate 20 or polysorbate 80 (the ASB of the instant application and the referenced application is identical).

The concentration of polysorbates and characteristics of the ASB and method used to produce ASB claimed in claims 37 and 40-41 are specific embodiments of the pharmaceutical composition described in the reference application. The specification of the reference application supports the recited enzyme in the pharmaceutical composition and the specific concentration of polysorbate 20 or polysorbate 80, characteristics of the ASB and methods of producing the ASB protein (pages 5-12) that would anticipate the pharmaceutical composition of claims 37 and 40-41 of the instant application. Claims 33-41 of the instant application cannot be considered patentably distinct over claims 1-16 of the reference application when there is specifically recited embodiment that would anticipate mainly claims 37 and 40-41 of the instant application. Alternatively, claims 37 and 40-41 of the instant application cannot be considered patentably distinct over claims 1-16 of the reference application because it would have been obvious to one having ordinary skill in the art to modify claims 1-16 of the reference by selecting a specifically disclosed embodiment that supports those claims, i.e. active enzyme and concentration of polysorbates used, methods of purifying ASB, etc. One of ordinary skill in the art would have been motivated to do this because the embodiments claimed in the instant claims are disclosed as being a preferred

Art Unit: 1652

embodiment within claims 1-16 of the reference application. Therefore, the conflicting claims are not patentably distinct from each other.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.


None of the claims are in condition for allowance.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Yong Pak whose telephone number is 571-272-0935. The examiner can normally be reached 6:30 A.M. to 5:00 P.M. Monday through Thursday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapu Achutamurthy can be reached on 571-272-0928. The fax phone numbers for the organization where this application or proceeding is assigned are 703-872-9306 for regular communications and 703-872-9307 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 571-272-1600.

Yong D. Pak  
Patent Examiner 1652

  
Rao Manjunath  
Primary Examiner 1652